Current and emerging ALS biomarkers: utility and potential in clinical trials

References

• Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med. 1994;330:585–591.
   PubMed Web of Science ®Google Scholar
• Writing G, Edaravone ALSSG. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16:505–512.
   PubMed Web of Science ®Google Scholar
• Center for Drug Evaluation and Research FaDA, US Department of Health and Human Services. Guidance for industry and FDA staff: qualification process for drug development tools. 2014
   Google Scholar
• Huynh W, Simon NG, Grosskreutz J, et al. Assessment of the upper motor neuron in amyotrophic lateral sclerosis. Clin Neurophysiol. 2016;127:2643–2660.
   PubMed Web of Science ®Google Scholar
• Al-Chalabi A, Hardiman O. The epidemiology of ALS: a conspiracy of genes, environment and time. Nat Rev Neurol. 2013;9:617–628.
   PubMed Web of Science ®Google Scholar
• Fujimura-Kiyono C, Kimura F, Ishida S, et al. Onset and spreading patterns of lower motor neuron involvements predict survival in sporadic amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2011;82:1244–1249.
   PubMed Web of Science ®Google Scholar
• Roche JC, Rojas-Garcia R, Scott KM, et al. A proposed staging system for amyotrophic lateral sclerosis. Brain. 2012;135:847–852.
   PubMed Web of Science ®Google Scholar
• Chio A, Logroscino G, Hardiman O, et al. Prognostic factors in ALS: a critical review. Amyotroph Lateral Scler. 2009;10:310–323.
   PubMed Web of Science ®Google Scholar
• Brooks BR, Miller RG, Swash M, et al. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1:293–299.
   PubMed Web of Science ®Google Scholar
• Balendra R, Jones A, Jivraj N, et al. Use of clinical staging in amyotrophic lateral sclerosis for phase 3 clinical trials. J Neurol Neurosurg Psychiatry. 2015;86:45–49.
   PubMed Web of Science ®Google Scholar
• Baumann F, Henderson RD, Morrison SC, et al. Use of respiratory function tests to predict survival in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2010;11:194–202.
   PubMed Web of Science ®Google Scholar
• Medical Research Council. Aids to the examination of the peripheral nervous system. London. Her Majesty's Stationery Office; 1976
   Google Scholar
• Goldstein LH, Abrahams S. Changes in cognition and behaviour in amyotrophic lateral sclerosis: nature of impairment and implications for assessment. Lancet Neurol. 2013;12:368–380.
   PubMed Web of Science ®Google Scholar
• Zou ZY, Zhou ZR, Che CH, et al. Genetic epidemiology of amyotrophic lateral sclerosis: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2017;88:540–549.
   PubMed Web of Science ®Google Scholar
• Williams KL, Fifita JA, Vucic S, et al. Pathophysiological insights into ALS with C9ORF72 expansions. J Neurol Neurosurg Psychiatry. 2013;84:931–935.
   PubMed Web of Science ®Google Scholar
• Andersen PM. Genetics of sporadic ALS. Amyotroph Lateral Scler Other Motor Neuron Disord. 2001;2(Suppl 1):S37–41.
   PubMedGoogle Scholar
• Cudkowicz ME, McKenna-Yasek D, Sapp PE, et al. Epidemiology of mutations in superoxide dismutase in amyotrophic lateral sclerosis. Ann Neurol. 1997;41:210–221.
   PubMed Web of Science ®Google Scholar
• Al-Chalabi A, van Den Berg LH, Veldink J. Gene discovery in amyotrophic lateral sclerosis: implications for clinical management. Nat Rev Neurol. 2017;13:96–104.
   PubMed Web of Science ®Google Scholar
• Finkel RS, Chiriboga CA, Vajsar J, et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. Lancet. 2016;388:3017–3026.
   PubMed Web of Science ®Google Scholar
• Miller TM, Pestronk A, David W, et al. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. Lancet Neurol. 2013;12:435–442.
   PubMed Web of Science ®Google Scholar
• Jiang J, Zhu Q, Gendron TF, et al. Gain of Toxicity from ALS/FTD-Linked Repeat Expansions in C9ORF72 Is Alleviated by Antisense Oligonucleotides Targeting GGGGCC-Containing RNAs. Neuron. 2016;90:535–550.
   PubMed Web of Science ®Google Scholar
• Shepheard SR, Chataway T, Schultz DW, et al. The extracellular domain of neurotrophin receptor p75 as a candidate biomarker for amyotrophic lateral sclerosis. PLoS One. 2014;9:e87398.
   PubMed Web of Science ®Google Scholar
• Ono S, Imai T, Matsubara S, et al. Decreased urinary concentrations of type IV collagen in amyotrophic lateral sclerosis. Acta Neurol Scand. 1999;100:111–116.
   PubMed Web of Science ®Google Scholar
• Lee MK, Marszalek JR, Cleveland DW. A mutant neurofilament subunit causes massive, selective motor neuron death: implications for the pathogenesis of human motor neuron disease. Neuron. 1994;13:975–988.
   PubMed Web of Science ®Google Scholar
• Brettschneider J, Petzold A, Sussmuth SD, et al. Axonal damage markers in cerebrospinal fluid are increased in ALS. Neurology. 2006;66:852–856.
   PubMed Web of Science ®Google Scholar
• Gaiottino J, Norgren N, Dobson R, et al. Increased neurofilament light chain blood levels in neurodegenerative neurological diseases. PLoS One. 2013;8:e75091.
   PubMed Web of Science ®Google Scholar
• Lu CH, Macdonald-Wallis C, Gray E, et al. Neurofilament light chain: a prognostic biomarker in amyotrophic lateral sclerosis. Neurology. 2015;84:2247–2257.
   PubMed Web of Science ®Google Scholar
• Xu Z, Henderson RD, David M, et al. Neurofilaments as Biomarkers for Amyotrophic Lateral Sclerosis: a Systematic Review and Meta-Analysis. PLoS One. 2016;11:e0164625.
   PubMed Web of Science ®Google Scholar
• Ganesalingam J, An J, Bowser R, et al. pNfH is a promising biomarker for ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14:146–149.
   PubMed Web of Science ®Google Scholar
• Oeckl P, Jardel C, Salachas F, et al. Multicenter validation of CSF neurofilaments as diagnostic biomarkers for ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2016;17:404–413.
   PubMed Web of Science ®Google Scholar
• Poesen K, De Schaepdryver M, Stubendorff B, et al. Neurofilament markers for ALS correlate with extent of upper and lower motor neuron disease. Neurology. 2017;88:2302–2309.
   PubMed Web of Science ®Google Scholar
• Feneberg E, Oeckl P, Steinacker P, et al. Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis. Neurology. 2018;90:e22–e30.
   PubMed Web of Science ®Google Scholar
• Rossi D, Volanti P, Brambilla L, et al. CSF neurofilament proteins as diagnostic and prognostic biomarkers for amyotrophic lateral sclerosis. J Neurol. 2018;265:510–521.
   PubMed Web of Science ®Google Scholar
• Ganesalingam J, An J, Shaw CE, et al. Combination of neurofilament heavy chain and complement C3 as CSF biomarkers for ALS. J Neurochem. 2011;117:528–537.
   PubMed Web of Science ®Google Scholar
• McCombe PA, Pfluger C, Singh P, et al. Serial measurements of phosphorylated neurofilament-heavy in the serum of subjects with amyotrophic lateral sclerosis. J Neurol Sci. 2015;353:122–129.
   PubMed Web of Science ®Google Scholar
• Boylan K, Yang C, Crook J, et al. Immunoreactivity of the phosphorylated axonal neurofilament H subunit (pNF-H) in blood of ALS model rodents and ALS patients: evaluation of blood pNF-H as a potential ALS biomarker. J Neurochem. 2009;111:1182–1191.
   PubMed Web of Science ®Google Scholar
• De Schaepdryver M, Jeromin A, Gille B, et al. Comparison of elevated phosphorylated neurofilament heavy chains in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2018;89:367–373.
   PubMed Web of Science ®Google Scholar
• Steinacker P, Feneberg E, Weishaupt J, et al. Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients. J Neurol Neurosurg Psychiatry. 2016;87:12–20.
   PubMed Web of Science ®Google Scholar
• Tortelli R, Ruggieri M, Cortese R, et al. Elevated cerebrospinal fluid neurofilament light levels in patients with amyotrophic lateral sclerosis: a possible marker of disease severity and progression. Eur J Neurol. 2012;19:1561–1567.
   PubMed Web of Science ®Google Scholar
• Gaiani A, Martinelli I, Bello L, et al. Diagnostic and Prognostic Biomarkers in Amyotrophic Lateral Sclerosis: neurofilament Light Chain Levels in Definite Subtypes of Disease. JAMA Neurol. 2017;74:525–532.
   PubMed Web of Science ®Google Scholar
• Reijn TS, Abdo WF, Schelhaas HJ, et al. CSF neurofilament protein analysis in the differential diagnosis of ALS. J Neurol. 2009;256:615–619.
   PubMed Web of Science ®Google Scholar
• Gille B, De Schaepdryver M, Goossens J, et al. Serum neurofilament light chain levels as a marker of upper motor neuron degeneration in patients with Amyotrophic Lateral Sclerosis. Neuropathol Appl Neurobiol. 2018;1–14.
   PubMedGoogle Scholar
• Gong ZY, Lv GP, Gao LN, et al. Neurofilament Subunit L Levels in the Cerebrospinal Fluid and Serum of Patients with Amyotrophic Lateral Sclerosis. Neurodegener Dis. 2018;18:165–172.
   PubMed Web of Science ®Google Scholar
• Menke RA, Gray E, Lu CH, et al. CSF neurofilament light chain reflects corticospinal tract degeneration in ALS. Ann Clin Transl Neurol. 2015;2:748–755.
   PubMed Web of Science ®Google Scholar
• Brettschneider J, Van Deerlin VM, Robinson JL, et al. Pattern of ubiquilin pathology in ALS and FTLD indicates presence of C9ORF72 hexanucleotide expansion. Acta Neuropathol. 2012;123:825–839.
   PubMed Web of Science ®Google Scholar
• Boylan KB, Glass JD, Crook JE, et al. Phosphorylated neurofilament heavy subunit (pNF-H) in peripheral blood and CSF as a potential prognostic biomarker in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2013;84:467–472.
   PubMed Web of Science ®Google Scholar
• Tortelli R, Copetti M, Ruggieri M, et al. Cerebrospinal fluid neurofilament light chain levels: marker of progression to generalized amyotrophic lateral sclerosis. Eur J Neurol. 2015;22:215–218.
   PubMed Web of Science ®Google Scholar
• Weydt P, Oeckl P, Huss A, et al. Neurofilament levels as biomarkers in asymptomatic and symptomatic familial amyotrophic lateral sclerosis. Ann Neurol. 2016;79:152–158.
   PubMed Web of Science ®Google Scholar
• Van Geel WJ, Rosengren LE, Verbeek MM. An enzyme immunoassay to quantify neurofilament light chain in cerebrospinal fluid. J Immunol Methods. 2005;296:179–185.
   PubMed Web of Science ®Google Scholar
• Wen X, Tan W, Westergard T, et al. Antisense proline-arginine RAN dipeptides linked to C9ORF72-ALS/FTD form toxic nuclear aggregates that initiate in vitro and in vivo neuronal death. Neuron. 2014;84:1213–1225.
   PubMed Web of Science ®Google Scholar
• Mackenzie IR, Arzberger T, Kremmer E, et al. Dipeptide repeat protein pathology in C9ORF72 mutation cases: clinico-pathological correlations. Acta Neuropathol. 2013;126:859–879.
   PubMed Web of Science ®Google Scholar
• Winer L, Srinivasan D, Chun S, et al. SOD1 in cerebral spinal fluid as a pharmacodynamic marker for antisense oligonucleotide therapy. JAMA Neurol. 2013;70:201–207.
   PubMed Web of Science ®Google Scholar
• Crisp MJ, Mawuenyega KG, Patterson BW, et al. In vivo kinetic approach reveals slow SOD1 turnover in the CNS. J Clin Invest. 2015;125:2772–2780.
   PubMed Web of Science ®Google Scholar
• Neumann M, Sampathu DM, Kwong LK, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130–133.
   PubMed Web of Science ®Google Scholar
• Mackenzie IR, Bigio EH, Ince PG, et al. Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann Neurol. 2007;61:427–434.
   PubMed Web of Science ®Google Scholar
• Chen-Plotkin AS, Lee VM, Trojanowski JQ. TAR DNA-binding protein 43 in neurodegenerative disease. Nat Rev Neurol. 2010;6:211–220.
   PubMed Web of Science ®Google Scholar
• Verstraete E, Kuiperij HB, van Blitterswijk MM, et al. TDP-43 plasma levels are higher in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2012;13:446–451.
   PubMed Web of Science ®Google Scholar
• Kasai T, Tokuda T, Ishigami N, et al. Increased TDP-43 protein in cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Acta Neuropathol. 2009;117:55–62.
   PubMed Web of Science ®Google Scholar
• Steinacker P, Hendrich C, Sperfeld AD, et al. TDP-43 in cerebrospinal fluid of patients with frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Arch Neurol. 2008;65:1481–1487.
   PubMed Web of Science ®Google Scholar
• Xiao S, Sanelli T, Chiang H, et al. Low molecular weight species of TDP-43 generated by abnormal splicing form inclusions in amyotrophic lateral sclerosis and result in motor neuron death. Acta Neuropathol. 2015;130:49–61.
   PubMed Web of Science ®Google Scholar
• Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136:215–233.
   PubMed Web of Science ®Google Scholar
• Hawley ZCE, Campos-Melo D, Droppelmann CA, et al. MotomiRs: miRNAs in Motor Neuron Function and Disease. Front Mol Neurosci. 2017;10:127.
   PubMed Web of Science ®Google Scholar
• Hoye ML, Koval ED, Wegener AJ, et al. MicroRNA Profiling Reveals Marker of Motor Neuron Disease in ALS Models. J Neurosci. 2017;37:5574–5586.
   PubMed Web of Science ®Google Scholar
• Campos-Melo D, Droppelmann CA, He Z, et al. Altered microRNA expression profile in Amyotrophic Lateral Sclerosis: a role in the regulation of NFL mRNA levels. Mol Brain. 2013;6:26.
   PubMed Web of Science ®Google Scholar
• Benigni M, Ricci C, Jones AR, et al. Identification of miRNAs as Potential Biomarkers in Cerebrospinal Fluid from Amyotrophic Lateral Sclerosis Patients. Neuromolecular Med. 2016;18:551–560.
   PubMed Web of Science ®Google Scholar
• Freischmidt A, Muller K, Ludolph AC, et al. Systemic dysregulation of TDP-43 binding microRNAs in amyotrophic lateral sclerosis. Acta Neuropathol Commun. 2013;1:42.
   PubMed Web of Science ®Google Scholar
• De Felice B, Annunziata A, Fiorentino G, et al. miR-338-3p is over-expressed in blood, CFS, serum and spinal cord from sporadic amyotrophic lateral sclerosis patients. Neurogenetics. 2014;15:243–253.
   PubMed Web of Science ®Google Scholar
• Freischmidt A, Muller K, Zondler L, et al. Serum microRNAs in sporadic amyotrophic lateral sclerosis. Neurobiol Aging. 2015;36(2660):e15–20.
   Google Scholar
• Takahashi I, Hama Y, Matsushima M, et al. Identification of plasma microRNAs as a biomarker of sporadic Amyotrophic Lateral Sclerosis. Mol Brain. 2015;8:67.
   PubMed Web of Science ®Google Scholar
• Jia R, Shepheard S, Jin J, et al. Urinary Extracellular Domain of Neurotrophin Receptor p75 as a Biomarker for Amyotrophic Lateral Sclerosis in a Chinese cohort. Sci Rep. 2017;7:5127.
   PubMed Web of Science ®Google Scholar
• Shepheard SR, Wuu J, Cardoso M, et al. Urinary p75(ECD): a prognostic, disease progression, and pharmacodynamic biomarker in ALS. Neurology. 2017;88:1137–1143.
   PubMed Web of Science ®Google Scholar
• Xanthos DN, Sandkuhler J. Neurogenic neuroinflammation: inflammatory CNS reactions in response to neuronal activity. Nat Rev Neurosci. 2014;15:43–53.
   PubMed Web of Science ®Google Scholar
• Chen Y, Liu XH, Wu JJ, et al. Proteomic analysis of cerebrospinal fluid in amyotrophic lateral sclerosis. Exp Ther Med. 2016;11:2095–2106.
   PubMed Web of Science ®Google Scholar
• Ehrhart J, Smith AJ, Kuzmin-Nichols N, et al. Humoral factors in ALS patients during disease progression. J Neuroinflammation. 2015;12:127.
   PubMed Web of Science ®Google Scholar
• Houi K, Kobayashi T, Kato S, et al. Increased plasma TGF-beta1 in patients with amyotrophic lateral sclerosis. Acta Neurol Scand. 2002;106:299–301.
   PubMed Web of Science ®Google Scholar
• Lu CH, Allen K, Oei F, et al. Systemic inflammatory response and neuromuscular involvement in amyotrophic lateral sclerosis. Neurol Neuroimmunol Neuroinflamm. 2016;3:e244.
   PubMed Web of Science ®Google Scholar
• Cereda C, Baiocchi C, Bongioanni P, et al. TNF and sTNFR1/2 plasma levels in ALS patients. J Neuroimmunol. 2008;194:123–131.
   PubMed Web of Science ®Google Scholar
• Lunetta C, Lizio A, Maestri E, et al. Serum C-Reactive Protein as a Prognostic Biomarker in Amyotrophic Lateral Sclerosis. JAMA Neurol. 2017;74:660–667.
   PubMed Web of Science ®Google Scholar
• Miller RG, Block G, Katz JS, et al. Randomized phase 2 trial of NP001-a novel immune regulator: safety and early efficacy in ALS. Neurol Neuroimmunol Neuroinflamm. 2015;2:e100.
   PubMed Web of Science ®Google Scholar
• Smith R, Myers K, Ravits J, et al. Amyotrophic lateral sclerosis: is the spinal fluid pathway involved in seeding and spread? Med Hypotheses. 2015;85:576–583.
   PubMed Web of Science ®Google Scholar
• Henkel JS, Beers DR, Wen S, et al. Regulatory T-lymphocytes mediate amyotrophic lateral sclerosis progression and survival. EMBO Mol Med. 2013;5:64–79.
   PubMed Web of Science ®Google Scholar
• Chiu IM, Chen A, Zheng Y, et al. T lymphocytes potentiate endogenous neuroprotective inflammation in a mouse model of ALS. Proc Natl Acad Sci U S A. 2008;105:17913–17918.
   PubMed Web of Science ®Google Scholar
• Beers DR, Zhao W, Wang J, et al. ALS patients’ regulatory T lymphocytes are dysfunctional, and correlate with disease progression rate and severity. JCI Insight. 2017;2:e89530.
   PubMed Web of Science ®Google Scholar
• Sheean RK, McKay FC, Cretney E, et al. Association of Regulatory T-Cell Expansion With Progression of Amyotrophic Lateral Sclerosis: A Study of Humans and a Transgenic Mouse Model. JAMA Neurol. 2018;75:681–689.
   PubMed Web of Science ®Google Scholar
• Thonhoff JR, Beers DR, Zhao W, et al. Expanded autologous regulatory T-lymphocyte infusions in ALS: A phase I, first-in-human study. Neurol Neuroimmunol Neuroinflamm. 2018;5:e465.
   PubMed Web of Science ®Google Scholar
• Brites D, Vaz AR. Microglia centered pathogenesis in ALS: insights in cell interconnectivity. Front Cell Neurosci. 2014;8:117.
   PubMed Web of Science ®Google Scholar
• Steinacker P, Verde F, Fang L, et al. Chitotriosidase (CHIT1) is increased in microglia and macrophages in spinal cord of amyotrophic lateral sclerosis and cerebrospinal fluid levels correlate with disease severity and progression. J Neurol Neurosurg Psychiatry. 2018;89:239–247.
   PubMed Web of Science ®Google Scholar
• Martinez-Merino L, Iridoy M, Galbete A, et al. Evaluation of Chitotriosidase and CC-Chemokine Ligand 18 as Biomarkers of Microglia Activation in Amyotrophic Lateral Sclerosis. Neurodegener Dis. 2018;18:208–215.
   PubMed Web of Science ®Google Scholar
• Thompson AG, Gray E, Thezenas ML, et al. Cerebrospinal fluid macrophage biomarkers in amyotrophic lateral sclerosis. Ann Neurol. 2018;83:258–268.
   PubMed Web of Science ®Google Scholar
• Pagliardini V, Pagliardini S, Corrado L, et al. Chitotriosidase and lysosomal enzymes as potential biomarkers of disease progression in amyotrophic lateral sclerosis: a survey clinic-based study. J Neurol Sci. 2015;348:245–250.
   PubMed Web of Science ®Google Scholar
• Tefera TW, Borges K. Metabolic Dysfunctions in Amyotrophic Lateral Sclerosis Pathogenesis and Potential Metabolic Treatments. Front Neurosci. 2016;10:611.
   PubMed Web of Science ®Google Scholar
• Zoccolella S, Simone IL, Capozzo R, et al. An exploratory study of serum urate levels in patients with amyotrophic lateral sclerosis. J Neurol. 2011;258:238–243.
   PubMed Web of Science ®Google Scholar
• Ascherio A, LeWitt PA, Xu K, et al. Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol. 2009;66:1460–1468.
   PubMed Web of Science ®Google Scholar
• Auinger P, Kieburtz K, McDermott MP. The relationship between uric acid levels and Huntington’s disease progression. Mov Disord. 2010;25:224–228.
   PubMed Web of Science ®Google Scholar
• Keizman D, Ish-Shalom M, Berliner S, et al. Low uric acid levels in serum of patients with ALS: further evidence for oxidative stress? J Neurol Sci. 2009;285:95–99.
   PubMed Web of Science ®Google Scholar
• Ikeda K, Hirayama T, Takazawa T, et al. Relationships between disease progression and serum levels of lipid, urate, creatinine and ferritin in Japanese patients with amyotrophic lateral sclerosis: a cross-sectional study. Intern Med. 2012;51:1501–1508.
   PubMed Web of Science ®Google Scholar
• Zach N, Ennist DL, Taylor AA, et al. Being PRO-ACTive: what can a Clinical Trial Database Reveal About ALS? Neurotherapeutics. 2015;12:417–423.
   PubMed Web of Science ®Google Scholar
• Atassi N, Berry J, Shui A, et al. The PRO-ACT database: design, initial analyses, and predictive features. Neurology. 2014;83:1719–1725.
   PubMed Web of Science ®Google Scholar
• Chio A, Calvo A, Bovio G, et al. Amyotrophic lateral sclerosis outcome measures and the role of albumin and creatinine: a population-based study. JAMA Neurol. 2014;71:1134–1142.
   PubMed Web of Science ®Google Scholar
• Paganoni S, Deng J, Jaffa M, et al. Body mass index, not dyslipidemia, is an independent predictor of survival in amyotrophic lateral sclerosis. Muscle Nerve. 2011;44:20–24.
   PubMed Web of Science ®Google Scholar
• Marin B, Desport JC, Kajeu P, et al. Alteration of nutritional status at diagnosis is a prognostic factor for survival of amyotrophic lateral sclerosis patients. J Neurol Neurosurg Psychiatry. 2011;82:628–634.
   PubMed Web of Science ®Google Scholar
• Wills AM, Hubbard J, Macklin EA, et al. Hypercaloric enteral nutrition in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet. 2014;383:2065–2072.
   PubMed Web of Science ®Google Scholar
• Lawton KA, Brown MV, Alexander D, et al. Plasma metabolomic biomarker panel to distinguish patients with amyotrophic lateral sclerosis from disease mimics. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15:362–370.
   PubMed Web of Science ®Google Scholar
• Konrad C, Kawamata H, Bredvik KG, et al. Fibroblast bioenergetics to classify amyotrophic lateral sclerosis patients. Mol Neurodegener. 2017;12:76.
   PubMed Web of Science ®Google Scholar
• Wainger BJ, Kiskinis E, Mellin C, et al. Intrinsic membrane hyperexcitability of amyotrophic lateral sclerosis patient-derived motor neurons. Cell Rep. 2014;7:1–11.
   PubMed Web of Science ®Google Scholar
• Richard JP, Maragakis NJ. Induced pluripotent stem cells from ALS patients for disease modeling. Brain Res. 2015;1607:15–25.
   PubMed Web of Science ®Google Scholar
• Tagerud S, Libelius R, Magnusson C. Muscle Nogo-A: a marker for amyotrophic lateral sclerosis or for denervation? Ann Neurol. 2007;62:676.
   PubMed Web of Science ®Google Scholar
• Meininger V, Pradat PF, Corse A, et al. Safety, pharmacokinetic, and functional effects of the nogo-a monoclonal antibody in amyotrophic lateral sclerosis: a randomized, first-in-human clinical trial. PLoS One. 2014;9:e97803.
   PubMed Web of Science ®Google Scholar
• Cornblath DR, Kuncl RW, Mellits ED, et al. Nerve conduction studies in amyotrophic lateral sclerosis. Muscle Nerve. 1992;15:1111–1115.
   PubMed Web of Science ®Google Scholar
• Neuwirth C, Nandedkar S, Stalberg E, et al. Motor unit number index (MUNIX): a novel neurophysiological technique to follow disease progression in amyotrophic lateral sclerosis. Muscle Nerve. 2010;42:379–384.
   PubMed Web of Science ®Google Scholar
• Shefner JM, Watson ML, Simionescu L, et al. Multipoint incremental motor unit number estimation as an outcome measure in ALS. Neurology. 2011;77:235–241.
   PubMed Web of Science ®Google Scholar
• Cheah BC, Vucic S, Krishnan AV, et al. Neurophysiological index as a biomarker for ALS progression: validity of mixed effects models. Amyotroph Lateral Scler. 2011;12:33–38.
   PubMed Web of Science ®Google Scholar
• Neuwirth C, Nandedkar S, Stalberg E, et al. Motor Unit Number Index (MUNIX): a novel neurophysiological marker for neuromuscular disorders; test-retest reliability in healthy volunteers. Clin Neurophysiol. 2011;122:1867–1872.
   PubMed Web of Science ®Google Scholar
• Felice KJ. A longitudinal study comparing thenar motor unit number estimates to other quantitative tests in patients with amyotrophic lateral sclerosis. Muscle Nerve. 1997;20:179–185.
   PubMed Web of Science ®Google Scholar
• Shefner JM, Cudkowicz ME, Schoenfeld D, et al. A clinical trial of creatine in ALS. Neurology. 2004;63:1656–1661.
   PubMed Web of Science ®Google Scholar
• Rutkove SB, Aaron R, Shiffman CA. Localized bioimpedance analysis in the evaluation of neuromuscular disease. Muscle Nerve. 2002;25:390–397.
   PubMed Web of Science ®Google Scholar
• Rutkove SB, Lee KS, Shiffman CA, et al. Test-retest reproducibility of 50 kHz linear-electrical impedance myography. Clin Neurophysiol. 2006;117:1244–1248.
   PubMed Web of Science ®Google Scholar
• Rutkove SB, Caress JB, Cartwright MS, et al. Electrical impedance myography correlates with standard measures of ALS severity. Muscle Nerve. 2014;49:441–443.
   PubMed Web of Science ®Google Scholar
• Rutkove SB, Caress JB, Cartwright MS, et al. Electrical impedance myography as a biomarker to assess ALS progression. Amyotroph Lateral Scler. 2012;13:439–445.
   PubMed Web of Science ®Google Scholar
• Wang LL, Spieker AJ, Li J, et al. Electrical impedance myography for monitoring motor neuron loss in the SOD1 G93A amyotrophic lateral sclerosis rat. Clin Neurophysiol. 2011;122:2505–2511.
   PubMed Web of Science ®Google Scholar
• Kanai K, Kuwabara S, Misawa S, et al. Altered axonal excitability properties in amyotrophic lateral sclerosis: impaired potassium channel function related to disease stage. Brain. 2006;129:953–962.
   PubMed Web of Science ®Google Scholar
• Vucic S, Lin CS, Cheah BC, et al. Riluzole exerts central and peripheral modulating effects in amyotrophic lateral sclerosis. Brain. 2013;136:1361–1370.
   PubMed Web of Science ®Google Scholar
• Geevasinga N, Menon P, Ng K, et al. Riluzole exerts transient modulating effects on cortical and axonal hyperexcitability in ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2016;17:580–588.
   PubMed Web of Science ®Google Scholar
• Kanai K, Shibuya K, Kuwabara S. [Motor axonal excitability properties are strong predictors for survival in amyotrophic lateral sclerosis]. Rinsho Shinkeigaku. 2011;51:1118–1119.
   PubMedGoogle Scholar
• Vucic S, Kiernan MC. Novel threshold tracking techniques suggest that cortical hyperexcitability is an early feature of motor neuron disease. Brain. 2006;129:2436–2446.
   PubMed Web of Science ®Google Scholar
• Vucic S, Nicholson GA, Kiernan MC. Cortical hyperexcitability may precede the onset of familial amyotrophic lateral sclerosis. Brain. 2008;131:1540–1550.
   PubMed Web of Science ®Google Scholar
• Floyd AG, Yu QP, Piboolnurak P, et al. Transcranial magnetic stimulation in ALS: utility of central motor conduction tests. Neurology. 2009;72:498–504.
   PubMed Web of Science ®Google Scholar
• Mills KR. The natural history of central motor abnormalities in amyotrophic lateral sclerosis. Brain. 2003;126:2558–2566.
   PubMed Web of Science ®Google Scholar
• Park SB, Vucic S, Cheah BC, et al. Flecainide in Amyotrophic Lateral Sclerosis as a Neuroprotective Strategy (FANS): A Randomized Placebo-Controlled Trial. EBioMedicine. 2015;2:1916–1922.
   PubMed Web of Science ®Google Scholar
• Whitwell JL. Voxel-based morphometry: an automated technique for assessing structural changes in the brain. J Neurosci. 2009;29:9661–9664.
   PubMed Web of Science ®Google Scholar
• Menke RA, Korner S, Filippini N, et al. Widespread grey matter pathology dominates the longitudinal cerebral MRI and clinical landscape of amyotrophic lateral sclerosis. Brain. 2014;137:2546–2555.
   PubMed Web of Science ®Google Scholar
• Agosta F, Pagani E, Rocca MA, et al. Voxel-based morphometry study of brain volumetry and diffusivity in amyotrophic lateral sclerosis patients with mild disability. Hum Brain Mapp. 2007;28:1430–1438.
   PubMed Web of Science ®Google Scholar
• Shen D, Cui L, Fang J, et al. Voxel-Wise Meta-Analysis of Gray Matter Changes in Amyotrophic Lateral Sclerosis. Front Aging Neurosci. 2016;8:64.
   PubMed Web of Science ®Google Scholar
• Agosta F, Gorno-Tempini ML, Pagani E, et al. Longitudinal assessment of grey matter contraction in amyotrophic lateral sclerosis: A tensor based morphometry study. Amyotroph Lateral Scler. 2009;10:168–174.
   PubMed Web of Science ®Google Scholar
• Schuster C, Kasper E, Machts J, et al. Focal thinning of the motor cortex mirrors clinical features of amyotrophic lateral sclerosis and their phenotypes: a neuroimaging study. J Neurol. 2013;260:2856–2864.
   PubMed Web of Science ®Google Scholar
• Walhout R, Schmidt R, Westeneng HJ, et al. Brain morphologic changes in asymptomatic C9orf72 repeat expansion carriers. Neurology. 2015;85:1780–1788.
   PubMed Web of Science ®Google Scholar
• Verstraete E, Veldink JH, Hendrikse J, et al. Structural MRI reveals cortical thinning in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2012;83:383–388.
   PubMed Web of Science ®Google Scholar
• Schuster C, Kasper E, Machts J, et al. Longitudinal course of cortical thickness decline in amyotrophic lateral sclerosis. J Neurol. 2014;261:1871–1880.
   PubMed Web of Science ®Google Scholar
• Agosta F, Pagani E, Petrolini M, et al. Assessment of white matter tract damage in patients with amyotrophic lateral sclerosis: a diffusion tensor MR imaging tractography study. AJNR Am J Neuroradiol. 2010;31:1457–1461.
   PubMed Web of Science ®Google Scholar
• van der Graaff MM, Sage CA, Caan MW, et al. Upper and extra-motoneuron involvement in early motoneuron disease: a diffusion tensor imaging study. Brain. 2011;134:1211–1228.
   PubMed Web of Science ®Google Scholar
• Chapman MC, Jelsone-Swain L, Johnson TD, et al. Diffusion tensor MRI of the corpus callosum in amyotrophic lateral sclerosis. J Magn Reson Imaging. 2014;39:641–647.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Schuff N, Woolley SC, et al. Progression of white matter degeneration in amyotrophic lateral sclerosis: a diffusion tensor imaging study. Amyotroph Lateral Scler. 2011;12:421–429.
   PubMed Web of Science ®Google Scholar
• Keil C, Prell T, Peschel T, et al. Longitudinal diffusion tensor imaging in amyotrophic lateral sclerosis. BMC Neurosci. 2012;13:141.
   PubMed Web of Science ®Google Scholar
• El Mendili MM, Cohen-Adad J, Pelegrini-Issac M, et al. Multi-parametric spinal cord MRI as potential progression marker in amyotrophic lateral sclerosis. PLoS One. 2014;9:e95516.
   PubMed Web of Science ®Google Scholar
• Cardenas-Blanco A, Machts J, Acosta-Cabronero J, et al. Structural and diffusion imaging versus clinical assessment to monitor amyotrophic lateral sclerosis. Neuroimage Clin. 2016;11:408–414.
   PubMed Web of Science ®Google Scholar
• Foerster BR, Dwamena BA, Petrou M, et al. Diagnostic accuracy of diffusion tensor imaging in amyotrophic lateral sclerosis: a systematic review and individual patient data meta-analysis. Acad Radiol. 2013;20:1099–1106.
   PubMed Web of Science ®Google Scholar
• Bowen BC, Pattany PM, Bradley WG, et al. MR imaging and localized proton spectroscopy of the precentral gyrus in amyotrophic lateral sclerosis. AJNR Am J Neuroradiol. 2000;21:647–658.
   PubMed Web of Science ®Google Scholar
• Pyra T, Hui B, Hanstock C, et al. Combined structural and neurochemical evaluation of the corticospinal tract in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2010;11:157–165.
   PubMed Web of Science ®Google Scholar
• Unrath A, Ludolph AC, Kassubek J. Brain metabolites in definite amyotrophic lateral sclerosis. A longitudinal proton magnetic resonance spectroscopy study. J Neurol. 2007;254:1099–1106.
   PubMed Web of Science ®Google Scholar
• Pohl C, Block W, Traber F, et al. Proton magnetic resonance spectroscopy and transcranial magnetic stimulation for the detection of upper motor neuron degeneration in ALS patients. J Neurol Sci. 2001;190:21–27.
   PubMed Web of Science ®Google Scholar
• Pagani M, Chio A, Valentini MC, et al. Functional pattern of brain FDG-PET in amyotrophic lateral sclerosis. Neurology. 2014;83:1067–1074.
   PubMed Web of Science ®Google Scholar
• Van Laere K, Vanhee A, Verschueren J, et al. Value of 18fluorodeoxyglucose-positron-emission tomography in amyotrophic lateral sclerosis: a prospective study. JAMA Neurol. 2014;71:553–561.
   PubMed Web of Science ®Google Scholar
• Zurcher NR, Loggia ML, Lawson R, et al. Increased in vivo glial activation in patients with amyotrophic lateral sclerosis: assessed with [(11)C]-PBR28. Neuroimage Clin. 2015;7:409–414.
   PubMed Web of Science ®Google Scholar
• Levine TD, Bowser R, Hank N, et al. A pilot trial of memantine and riluzole in ALS: correlation to CSF biomarkers. Amyotroph Lateral Scler. 2010;11:514–519.
   PubMed Web of Science ®Google Scholar
• Gomeni R, Fava M. Pooled Resource Open-Access ALSCTC. Amyotrophic lateral sclerosis disease progression model. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15:119–129.
   PubMed Web of Science ®Google Scholar
• Berry JD, Taylor AA, Beaulieu D, et al. Improved stratification of ALS clinical trials using predicted survival. Ann Clin Transl Neurol. 2018;5:474–485.
   PubMed Web of Science ®Google Scholar
• Cudkowicz ME, Shefner JM, Schoenfeld DA, et al. Trial of celecoxib in amyotrophic lateral sclerosis. Ann Neurol. 2006;60:22–31.
   PubMed Web of Science ®Google Scholar
• Stommel EW, Cohen JA, Fadul CE, et al. Efficacy of thalidomide for the treatment of amyotrophic lateral sclerosis: a phase II open label clinical trial. Amyotroph Lateral Scler. 2009;10:393–404.
   PubMed Web of Science ®Google Scholar
• Benatar M, Wuu J, Andersen PM, et al. Randomized, double-blind, placebo-controlled trial of arimoclomol in rapidly progressive SOD1 ALS. Neurology. 2018;90:e565–e74.
   PubMed Web of Science ®Google Scholar
• Fiala M, Mizwicki MT, Weitzman R, et al. Tocilizumab infusion therapy normalizes inflammation in sporadic ALS patients. Am J Neurodegener Dis. 2013;2:129–139.
   PubMedGoogle Scholar
• Lange DJ, Andersen PM, Remanan R, et al. Pyrimethamine decreases levels of SOD1 in leukocytes and cerebrospinal fluid of ALS patients: a phase I pilot study. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14:199–204.
   PubMed Web of Science ®Google Scholar
• Bozik ME, Mitsumoto H, Brooks BR, et al. A post hoc analysis of subgroup outcomes and creatinine in the phase III clinical trial (EMPOWER) of dexpramipexole in ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15:406–413.
   PubMed Web of Science ®Google Scholar
• Maier A, Deigendesch N, Muller K, et al. Interleukin-1 Antagonist Anakinra in Amyotrophic Lateral Sclerosis–A Pilot Study. PLoS One. 2015;10:e0139684.
   PubMed Web of Science ®Google Scholar
• Macchi Z, Wang Y, Moore D, et al. A multi-center screening trial of rasagiline in patients with amyotrophic lateral sclerosis: possible mitochondrial biomarker target engagement. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16:345–352.
   PubMed Web of Science ®Google Scholar
• Fournier CN, Schoenfeld D, Berry JD, et al. An open label study of a novel immunosuppression intervention for the treatment of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2018;19:242–249.
   PubMed Web of Science ®Google Scholar
• Berry JD, Paganoni S, Atassi N, et al. Phase IIa trial of fingolimod for amyotrophic lateral sclerosis demonstrates acceptable acute safety and tolerability. Muscle Nerve. 2017;56:1077–1084.
   PubMed Web of Science ®Google Scholar